ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2917

Inhibition of PAD4 Activity and the Formation of Neutrophil Extracellular Traps Via PTPN22, but Not Its Rheumatoid Arthritis-Prone W620 Variant

I-Cheng Ho1, Hui-Hsin Chang1, Nishant Dwivedi1, Hsiao-Wei Tsao1 and Anthony Nicholas2, 1Medicine, Brigham and Women's Hospital, Boston, MA, 2Neurology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: citrullination and rheumatoid arthritis (RA), NETosis, PAD

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

One unique feature of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibody (ACPA). Protein citrullination, a process mediated by peptidyl arginine deiminases, such as PAD4, not only yields antigens recognized by ACPA but also contributes to RA through several other mechanisms including promotion of neutrophil extracellular traps (NET) formation. A C-to-T single nucleotide polymorphism (SNP) located at position 1858 of human PTPN22, a protein tyrosine phosphatase, carries an odds ratio of 2-3 and, together with HLA alleles containing shared epitopes, synergistically increases the risk of RA 20- to 30-fold. The effect of this SNP is limited to ACPA+ RA. An explanation for this unique association is still lacking. We postulate that PTPN22 and the C1858T SNP, which converts an arginine (R620) to a tryptophan, influence protein citrullination.

Methods:

The level of citrullinated proteins in wild type and PTPN22-deficient cells, as well as PBMC from healthy donors carrying or not carrying the risk T allele was examined with Western blotting using F95 antibody and anti-citrullinated histone H3.  Co-immunoprecipitation was used to examine the physical interaction between PTPN22 and PAD4. The formation of neutrophil extracellular traps was analyzed with Sy-tox uptake and immunocytochemistry.

Results:

Impaired expression of PTPN22 resulted in hypercitrullination in mouse and human immune cells. This effect was partly mediated by PAD4.  PTPN22 did not regulate the expression or tyrosine phosphorylation of PAD4. Instead, PTPN22 physically interacted with and suppressed the activity of PAD4 independently of its phosphatase activity. Conversion of the R620 to a tryptophan disrupted the interaction between PTPN22 and PAD4, and completely ablated the ability of PTPN22 to suppress protein citrullination. Accordingly, the risk T allele is associated with hypercitrullination in PBMC and heightened propensity to form NET in healthy donors.

Conclusion: PTPN22 is a natural inhibitor of PAD, and the R620 is critical for this non-phosphatase function of PTPN22. The C1858T-mediated conversion of R620 to tryptophan increases the risk of ACPA+ RA through hypercitrullination and heightened propensity to form NET. Our data also identify a novel pathway regulating PAD activity and establish a molecular connection between the two RA risk genes PTPN22 and PAD4.


Disclosure:

I. C. Ho,
None;

H. H. Chang,
None;

N. Dwivedi,
None;

H. W. Tsao,
None;

A. Nicholas,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-pad4-activity-and-the-formation-of-neutrophil-extracellular-traps-via-ptpn22-but-not-its-rheumatoid-arthritis-prone-w620-variant/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology